Mathematical modeling of the neutrophil production process supported by administration of glycoprotein

• Autorzy: Mika Barbara , Pelka Magdalena , Tkacz Ewaryst

Identyfikatory

DOI

10.1016/j.bbe.2020.12.001

• Języki publikacji: EN

Abstrakty

EN

Drugs administered in chemotherapy influence the patient's hematopoietic system. The side effects of chemotherapy can force changes in both the dose of drugs and the schedule of their administration, which in turn may adversely affect the patient's health. During chemotherapy treatment, there is a necessity to continuously monitor basic blood parameters, including the number of neutrophils and blood platelets, responsible for the patient's immunity. The aim of this paper is to study the behavior of the hematopoietic system, during chemotherapy, by means of a modified mathematical model of neutrophil production. We conducted simulations for children from 1–15 years old, suffering from neuroblastoma, who are undergoing chemotherapy treatment with Topotecan (TPT). The proposed model provides an effective tool for signaling the moment when the number of mature neutrophils, circulating in the blood, drops below the critical level, that is, 500 cells/mL. Such a nadir persisting over time may result in severe neutropenia and consequently require a halt or change to the established treatment schedule. In addition, we analyzed the process of neutrophil production during chemotherapy, supported by the application of glycoprotein as a growth factor of stem cells.

Słowa kluczowe

EN

cancer; chemotherapy; glycoprotein; neutrophils; Topotecan

PL

nowotwór; chemioterapia; glikoproteina; neutrofile; Topotecan

• Wydawca: Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences ; Elsevier
• Czasopismo: Biocybernetics and Biomedical Engineering
• Rocznik: 2021
• Tom: Vol. 41, no. 1
• Strony: 45--63
• Opis fizyczny: Bibliogr. 49 poz., rys., tab., wykr.

Twórcy

autor

Mika Barbara

• Silesian University of Technology, Faculty of Biomedical Engineering, Department of Biosensors and Processing of Biomedical Signals, Zabrze, Poland

autor

Pelka Magdalena

• Silesian University of Technology, Faculty of Biomedical Engineering, Department of Biosensors and Processing of Biomedical Signals, Zabrze, Poland

autor

Tkacz Ewaryst

• Silesian University of Technology, Faculty of Biomedical Engineering, Department of Biosensors and Processing of Biomedical Signals, Zabrze, Poland

Bibliografia

• [1] Mouser CL, Antoniou ES, Tadros J, Vassiliou EK. A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent. Theor Biol Med Model 2014;11:4.
• [2] de Pillis L, Fister KR, Gu W, Collins C, Daub M, Gross D, et al. Mathematical model creation for cancer chemo- immunotherapy. Comput Math Methods Med 2009;10 (3):165–84.
• [3] Dolbniak M, Swierniak A. Comparison of simple models of periodic protocols for combined anticancer therapy. Computational and Mathematical Methods in Medicine 2013 2013.
• [4] Jord ao G, Tavares JN. Mathematical models in cancer therapy. BioSystems 2017;162:12–23.
• [5] Ansarizadeh F, Singh M, Richards D. Modelling of tumor cells regression in response to chemotherapeutic treatment. Appl Math Model 2017;48:96–112.
• [6] Wang H, Lin C, Fan W, Zhang J, Zhang Y, Yao W, et al. Dynamic changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer Manag Res 2020;12:3433–44.
• [7] Ho T, Clermont G, Parker RS. A model of neutrophil dynamics in response to inflammatory and cancer chemotherapy challenges. Comput Chem Eng 2013;51:187–96.
• [8] Payne S, Miles D. Mechanisms of anticancer drugs. CRC Press; 2008. p. 34–46 [Ch. 1].
• [9] Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan – a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999;56 (1):1–12.
• [10] Tsuchida Y, Shitara T. Topotecan and irinotecan in the treatment of pediatric solid tumors. Curr Pediatr Rev 2005;1 (1):55–61.
• [11] Ashraf K, Shaikh F, Gibson P, Baruchel S, Irwin MS. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. Pediatr Blood Cancer 2013;60(10):1636–41.
• [12] Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9(2):633–40, http://clincancerres.aacrjournals.org/content/9/2/633.full. Pdf.
• [13] Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Salda na J, Guillén- Ponce C, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol/ Hematol 2018;131:16–23.
• [14] Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol: H&O 2012;10(12):825–6.
• [15] Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology 2015;29:282–94.
• [16] Chatfield SM, Thieblemont N, Witko- Sarsat V. Expanding neutrophil horizons: new concepts in inflammation. J Innate Immunity 2018;10(5–6):422–31.
• [17] Ali MR, Hossain MS, Islam MA, et al. Aspect of thrombolytic therapy: a review. Sci World J 2014;2014:8.
• [18] Celkan T, Koç BS. Approach to the patient with neutropenia in childhood. Turk Arch Pediatr/Türk Pediatr Ars 2015;50 (3):136–44.
• [19] Boxer LA. How to approach neutropenia. Hematology 2012;2012:174–82.
• [20] Walkovich K, Boxer LA. How to approach neutropenia in childhood. Pediatr Rev 2013;34(4):173–84.
• [21] Xie X, Shi Q, Wu P, Zhang X, Kambara H, Su J, et al. Single- cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol 2020;21(9):1119–33.
• [22] Câmara De Souza D, Craig M, Cassidy T, Li J, Nekka F, Bélair J, et al. Transit and lifespan in neutrophil production: implications for drug intervention. J Pharmacokinet pharmacodyn 2018;45(1):59–77.
• [23] Quirion E. Filgrastim and pegfilgrastim use in patients with neutropenia. Clin J Oncol Nurs 2009;13:324–8.
• [24] Frampton JE, Lee CR, Faulds D. Filgrastim. a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994;48:731–60.
• [25] Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Investig New Drugs 2003;21(2):183–94.
• [26] Quartino AL, Friberg LE, Karlsson MO. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Investig New Drugs 2012;30(2):833–45.
• [27] Panetta JC, Schaiquevich PS, Stewart VM, Clinton F. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for neuroblastoma. Clin J Oncol Nurs 2008;14:318–25.
• [28] Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol 2005;234(3):311–27.
• [29] Crauste F, Adimy M. Modeling and asymptotic stability of a growth factor-dependent stem cell dynamics model with distributed delay. Discrete Contin Dyn Syst Ser B 2007;8 (1):19–38.
• [30] Brooks G, Provencher G, Lei J, Mackey MC. Neutrophil dynamics after chemotherapy and G-CSF: the role of pharmacokinetics in shaping the response. J Theor Biol 2012;315:97–109.
• [31] Foley C, Mackey MC. Mathematical model for G-CSF administration after chemotherapy. J Theor Biol 2009;257:27–44.
• [32] Craig M, Humphries AR, Mackey MC. A mathematical model of granulopoiesis incorporating the negative feedback dynamics and kinetics of G-CSF/neutrophil binding and internalization. Bull Math Biol 2016;78 (12):2304–57.
• [33] Craig M. Towards quantitative systems pharmacology models of chemotherapy-induced neutropenia. CPT: Pharmacomet Syst Pharmacol 2017;6(5):293–304.
• [34] Pujo-Menjouet L. Blood cell dynamics: half of a century of modelling. Math Model Nat Phenom 2016;11(1):92–115.
• [35] Balamuralitharan S, Rajasekaran S. A parameter estimation model of G-CSF: mathematical model of cyclical neutropenia. Am J Comput Math 2012;2(1):12–20.
• [36] Collins C, Fister KR, Key B, Williams M. Blasting neuroblastoma using optimal control of chemotherapy. Math Biosci Eng 2009;6:451–67.
• [37] Colijn C, Foley C, Mackey MC. G-CSF treatment of canine cyclical neutropenia: a comprehensive mathematical model. Exp Hematol 2007;35(6):898–907.
• [38] Han-Ching T, Kuo-Hsuan C. Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma. Int J Psychiatry Med 2014;47:255–61.
• [39] Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 2011;85:23–8.
• [40] Friis-Hansen BJ. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961;28:169–81.
• [41] van den Anker JN, Tibboel D. Developmental physiology and pharmacotherapy in pediatric surgical newborns. In: Losty PD, Flake AW, Rintala RJ, Hutson JM, Iwai N, editors. Rickham's neonatal surgery, vol. 45. London: Springer; 2018. p. 169–83.
• [42] Coulthard MG. Surface area is best estimated from weight alone: pocket calculators and nomograms are unnecessary. Arch Dis Child 1994;71(3):281.
• [43] Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 2012;118(22):5663–70.
• [44] Santana WM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23:4039–47.
• [45] Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994;54 (5):1220–6.
• [46] Annex I – summary of product characteristic for topotecan; 2019. Available from: https://www.ema.europa.eu/en/ medicines/human/EPAR/topotecan-hospira#authorisation- details-section. [Accessed 14 June 2020].
• [47] National Center for Health Statistics. Available from: https://www.cdc.gov/growthcharts/html_charts/wtage. htm. [Accessed 2020].
• [48] Matthes K, Laubach AE, Wang E, Anderson T, editors. Pediatric anesthesiology. A comprehensive board review. Pediatric anesthesiology. Oxford: Oxford University Press; 2015. Available from: https://oxfordmedicine.com/view/ 10.1093/med/9780199398348.001.0001/med-9780199398348.
• [49] Del Monte U. Does the cell number 109 still really fit one gram of tumor tissue? Cell Cycle 2009;8(3):505–6.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).